US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

30.02

-1.3950-4.44%

Volume:45.72K

Turnover:1.38M

Market Cap:858.60M

PE:-11.57

High:30.95

Open:30.84

Low:29.68

Close:31.41

52wk High:33.47

52wk Low:13.36

Shares:28.61M

Float Shares:19.00M

Volume Ratio:0.99

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5941

EPS(LYR):-3.1329

ROE:-20.02%

ROA:-13.68%

PB:2.27

PE(LYR):-9.58

Loading ...

Overview Company News Filings

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.

LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)

LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million

Lb Pharmaceuticals Inc - Q4 Net Loss per Share $0.45

THOMSON REUTERS

Press Release: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Lb Pharmaceuticals Inc - Topline Data Expected in Second Half of 2027

THOMSON REUTERS

Lb Pharmaceuticals Initiates Pivotal Phase 3 Trial (Nova-2) for Lb-102 in Patients With Schizophrenia

THOMSON REUTERS

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB Pharmaceuticals director Zachary Prensky to retire from board at 2026 annual meeting

LB Pharmaceuticals adds neuroscience leader to board, governance

LB Pharmaceuticals appoints Robert Lenz to board

Press Release: LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

LB Pharmaceuticals to Present at Leerink 2026 Global Healthcare Conference and Stifel 2026 Virtual CNS Forum

LB Pharmaceuticals to Participate in Upcoming March Investor Events

LB Pharmaceuticals management to meet with Piper Sandler

LB Pharmaceuticals Grants Stock Options to New General Counsel Under Inducement Plan

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued

Lb Pharmaceuticals Announces $100.0 Million Private Placement

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LBRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":30.015,"timestamp":1778862721272,"preClose":31.41,"halted":0,"volume":45722,"delay":0,"changeRate":-0.04441260744985672,"floatShares":19000000,"shares":28605700,"eps":-2.594121,"marketStatus":"Trading","change":-1.395,"latestTime":"05-15 12:32:13 EDT","open":30.84,"high":30.95,"low":29.68,"amount":1380970.0508060001,"amplitude":0.040433,"askPrice":30.16,"askSize":1,"bidPrice":29.86,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.594121,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778875200000},"marketStatusCode":2,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":31.41,"postHourTrading":{"tag":"盘后","latestPrice":31.41,"preClose":31.41,"latestTime":"16:10 EDT","volume":290,"amount":9108.9,"timestamp":1778789404375,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.986452},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":19000000,"roa":"-13.68%","roe":"-20.02%","lyrEps":-3.132945,"volumeRatio":0.986452,"shares":28605700,"dividePrice":0,"high":30.95,"amplitude":0.040433,"preClose":31.41,"low":29.68,"week52Low":13.36,"pbRate":"2.27","week52High":33.47,"institutionHeld":0,"latestPrice":30.015,"committee":0.99005,"eps":-2.594121,"divideRate":0,"volume":45722,"delay":0,"ttmEps":-2.594121,"open":30.84,"prevYearClose":22.26,"prevWeekClose":31.97,"prevMonthClose":31.71,"prevQuarterClose":24.66,"fiveDayClose":31.97,"twentyDayClose":30.52,"sixtyDayClose":24.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1777348800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-05-13","current":-12.108148,"percent":0.678571,"low":-37.407457,"twenty":-32.316764,"median":-26.867851,"eighty":-12.552639,"high":-0.410019,"avg":-24.894735,"sd":8.51847,"marketCap":892704176},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-13","current":-22.917469,"twenty":-32.316764,"median":-26.867851,"eighty":-12.552639,"marketCap":892704176}],"updateTime":1778826068292},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622845792","title":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845792?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:54","pubTimestamp":1774598066,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex HoldingsMarch 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","ATAI","BK4134","GOOY","GOOW","GOOX","BK4561","NHI","BIOA","PL","MGTX","CCL","LU1815333072.USD","DIS","GGLL","GOOP","BK4551","SPXC","COP","OLPX","IE00BMPRXQ63.HKD","CHRD","PRMB","UNX","FISV","IMMX","KYIV","HAL","FOXA","MASI","GGLS","BALY","PHAT","PLU","ADP","LU0345769128.USD","GOOGL","DISO","LBRX","IT","EOG","U","BTGO","OXY","AGX","GNRC","OXM","CTAS","KOD","GOU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622089952","title":"LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089952","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089952?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:30","pubTimestamp":1774557043,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51496123/lb-pharmaceuticals-q4-eps-0-45-beats-0-63-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789989","title":"LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622789989?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:12","pubTimestamp":1774555927,"startTime":"0","endTime":"0","summary":"“2025 was a transformative year for LB. It began with the presentation of positive Phase 2 trial results of LB-102 in acute schizophrenia that supp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-reports-q4-eps-45c-consensus-32c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-reports-q4-eps-45c-consensus-32c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622962358","title":"LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622962358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622962358?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555786,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million. LB Pharmaceuticals filed a Form 8-K reporting Q4 and full-year 2025 results, including a Q4 net loss of USD 11.5 million and a full-year net loss of USD 25.2 million.Q4 R&D expense rose to USD 8.5 million, while Q4 G&A expense was USD 5.4 million.Full-year R&D expense fell 67.38% to USD 16.7 million, driven by lower spending on the Phase 2 acute schizophrenia trial that largely occurred in 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL1WGQdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899379","title":"Lb Pharmaceuticals Inc - Q4 Net Loss per Share $0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899379?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA5YLD1Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622989619","title":"Press Release: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989619?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"Reported positive results from potentially registrational Phase 2 trial of. Advanced LB-102 into late-stage development in multiple indications with initiation of. a pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trial. Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for the. adjunctive treatment of major depressive disorder  in early 2027. Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025,and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029. The Company is building a pipeline that leverages the broad therapeutic potential of LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.-- Reported positive results in January 2025 from a robust 359 patient Phase. 2 trial  of LB-102 in acute schizophrenia. The trial met the. baseline in the Positive and Negative Syndrome Scale  ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4233","BK4007","LB","BK4139","ABVC","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622539073","title":"Lb Pharmaceuticals Inc - Topline Data Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2622539073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622539073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUAPZFHS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073533","title":"Lb Pharmaceuticals Initiates Pivotal Phase 3 Trial (Nova-2) for Lb-102 in Patients With Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073533?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUAPZFHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622739280","title":"LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2622739280","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622739280?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440000,"startTime":"0","endTime":"0","summary":"LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262125/0/en/LB-Pharmaceuticals-Initiates-Pivotal-Phase-3-Trial-NOVA-2-for-LB-102-in-Patients-with-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","PSP","BK4007","BK4213","BK4233","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620491089","title":"LB Pharmaceuticals director Zachary Prensky to retire from board at 2026 annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491089","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491089?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:41","pubTimestamp":1773693689,"startTime":"0","endTime":"0","summary":"Zachary Prensky told the board of LB Pharmaceuticals that he plans to retire as a director and not stand for re-election at the 2026 annual meeting. He will remain on the board and on its Nominating and Corporate Governance Committee until the conclusion of the annual meeting. Prensky is expected to provide consulting services to the company after his board term ends. LB Pharmaceuticals said a transition agreement amendment effective June 3, 2026, allows Prensky’s unvested stock options to continue vesting during the term of the amended agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL1GJfVv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953962","title":"LB Pharmaceuticals adds neuroscience leader to board, governance","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953962?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:49","pubTimestamp":1773146988,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ( ($LBRX) ) has issued an update. On March 6, 2026, LB Pharmaceuticals appointed veteran neuroscience drug development exe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-adds-neuroscience-leader-to-board-governance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-adds-neuroscience-leader-to-board-governance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4213","LB","BK4233","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618362582","title":"LB Pharmaceuticals appoints Robert Lenz to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618362582","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618362582?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057701,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals appointed Robert Lenz, M.D., Ph.D. to its board of directors. Lenz most recently served as executive vice president and head of R&D at Neumora Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5Nc1ry:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","LBRX","BK4588","IE00B64PRP62.GBP","BK4007","SG9999014013.SGD","BK4112","BK4585","NMRA","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618529625","title":"Press Release: LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618529625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618529625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057660,"startTime":"0","endTime":"0","summary":"NEW YORK, March 09, 2026  -- LB Pharmaceuticals Inc  , a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder  and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors.\"We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications,\" said Heather Turner, Chief Executive Officer of LB Pharmaceuticals.LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive MDD, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the fir","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","BK4233","LBRX","BK4007","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569842","title":"LB Pharmaceuticals to Present at Leerink 2026 Global Healthcare Conference and Stifel 2026 Virtual CNS Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569842","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569842?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:08","pubTimestamp":1772658497,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals to Present at Leerink 2026 Global Healthcare Conference and Stifel 2026 Virtual CNS Forum               LB Pharmaceuticals Inc. will present at the Leerink 2026 Global Healthcare Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5XLsZ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","BK4588","LBRX","IE00BGHQF748.EUR","LU2210150020.SGD","LU2210149790.SGD","NDAQ","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569663","title":"LB Pharmaceuticals to Participate in Upcoming March Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569663","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569663?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:05","pubTimestamp":1772658300,"startTime":"0","endTime":"0","summary":"NEW YORK, March  04, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249722/0/en/LB-Pharmaceuticals-to-Participate-in-Upcoming-March-Investor-Events.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB","BK4233","BK4213","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612289553","title":"LB Pharmaceuticals management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2612289553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612289553?lang=en_us&edition=fundamental","pubTime":"2026-02-19 23:46","pubTimestamp":1771515994,"startTime":"0","endTime":"0","summary":"Meeting to be held in Boston on February 23 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","BK4233","LB","BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610671548","title":"LB Pharmaceuticals Grants Stock Options to New General Counsel Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610671548","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610671548?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:41","pubTimestamp":1770759703,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has granted Dr. Minako Pazdera, its new General Counsel, options to purchase 140,000 shares of the company's common stock. The options have a ten-year term and an exercise price of $24.22 per share, matching the closing price on the grant date of February 10, 2026. Vesting will occur over four years, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting in equal monthly installments over the following three years, contingent on Dr. Pazdera’s continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL2nsnYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","BK4585","LU0314104364.USD","SG9999014039.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LBRX","NDAQ","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610671903","title":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610671903","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610671903?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:41","pubTimestamp":1770759660,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb.  10, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/10/3235822/0/en/LB-Pharmaceuticals-Reports-Inducement-Grant-to-New-Employee-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4213","BK4233","LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609308957","title":"LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued","url":"https://stock-news.laohu8.com/highlight/detail?id=2609308957","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609308957?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:04","pubTimestamp":1770296645,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has announced the issuance of pre-funded warrants to purchase up to 1,417,107 shares of its common stock as part of a private placement. The pre-funded warrants were offered alongside 3,306,571 shares of common stock to select institutional investors. The purchase price for each pre-funded warrant is $21.1699, reflecting the per share purchase price for common stock less the $0.0001 per share exercise price. This private placement is expected to raise approximately $100 million in gross proceeds, with the funds intended to support a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder and for general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceutical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL60rzkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","BK4585","LU0314104364.USD","NDAQ","LBRX","IE00B64PRP62.GBP","BK4007","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609409370","title":"Lb Pharmaceuticals Announces $100.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2609409370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609409370?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA35DJXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}]}}